Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder:: A systematic literature review

被引:190
作者
Karsenty, Gilles [1 ]
Denys, Pierre [2 ]
Amarenco, Gerard [3 ]
De Seze, Marianne [4 ]
Game, Xavier [5 ]
Haab, Francois [6 ]
Kerdraon, Jacques [7 ]
Perrouin-Verbe, Brigitte [8 ]
Ruffion, Alain [9 ]
Saussine, Christian [10 ]
Soler, Jean-Marc [11 ]
Schurch, Brigitte [12 ]
Chartier-Kastler, Emmanuel [13 ]
机构
[1] Hosp St Marguerite, Marseille, France
[2] Hop Raymond Poincare, Garches, France
[3] Hosp Rothschild, F-75571 Paris, France
[4] Hosp Pellegrin, F-33076 Bordeaux, France
[5] Hosp Rangueil, Toulouse, France
[6] Hosp Tenon, Paris, France
[7] Fonctionnelles Kerpape, Ctr Mutualiste Reeducat & Readapt, Ploemeur, France
[8] Hosp St Jacques, Nantes, France
[9] Hosp Henry Gabrielle, St Genis Laval, France
[10] Hospices Civils Strasbourg, Strasbourg, France
[11] Ctr Bouffard Vercelli, Cerbere, France
[12] Hosp Univ Balgrist, Zurich, Switzerland
[13] Hosp La Pitie Salpetriere, Paris, France
关键词
botulinum toxin type A; cholinergic antagonist; overactive bladder; urinary bladder; neurogenic; urinary incontinence; urodynamics;
D O I
10.1016/j.eururo.2007.10.013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives: This systematic literature review discusses the efficacy and safety of botulinum toxin type A (Botox((R))) intradetrusor injections in adults with neurogenic detrusor overactivity (NDO) and urinary incontinence or overactive bladder symptoms of neurogenic origin (NOAB). Methods: A MEDLINE and EMBASE search for clinical studies with botulinum toxin A injected into the detrusor of adults with NDO was performed. For several efficacy and safety variables data were extracted by one person and independently quality-controlled by another person. Extracted data were reviewed to propose recommendations for use in clinical practice based on level of evidence and expert opinion. Results: A total of 18 articles evaluating the efficacy or safety of Botox in patients with NDO and incontinence/NOAB resistant to antimuscarinic therapy, with or without clean intermittent self-catheterisation (CIC), were selected. The amount of Botox injected was mostly 300 U, usually as 30 injections of 10 U/ml in the bladder (excluding the trigone) under cystoscopic guidance and with different types of anaesthesia. Most of the studies reported a significant improvement in clinical (approximately 40-80% of patients became completely dry between CICs) as well as urodynamic (in most studies mean maximum detrusor pressure was reduced to <= 40 cm H2O) variables and in the patients' quality of life, without major adverse events. Conclusions: Botox injections into the detrusor provide a clinically significant improvement in adults with NDO and incontinence/NOAB refractory to antimuscarinics. It seems to be very well tolerated. However, more adequately powered, well-designed, randomised, controlled studies evaluating the optimal dose, number and location of injections, impact on antimuscarinic regimen and CIC use, duration of effect, and when to perform repeat injections are warranted. (c) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:275 / 287
页数:13
相关论文
共 41 条
[1]
The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society (Reprinted from Neurourology and Urodynamics, vol 21, pg 167-178, 2002) [J].
Abrams, P ;
Cardozo, L ;
Fall, M ;
Griffiths, D ;
Rosier, P ;
Ulmsten, U ;
Van Kerrebroeck, P ;
Victor, A ;
Wein, A .
UROLOGY, 2003, 61 (01) :37-49
[2]
Using translational medicine to understand clinical differences between botulinum toxin formulations [J].
Aoki, K. R. ;
Ranoux, D. ;
Wissel, J. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 :10-19
[3]
Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions [J].
Bagi, P ;
Biering-Sorensen, F .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2004, 38 (06) :495-498
[4]
Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia [J].
Chapman, Mary Ann ;
Barron, Rich ;
Tanis, David C. ;
Gill, Chandler E. ;
Charles, P. David .
CLINICAL THERAPEUTICS, 2007, 29 (07) :1325-1337
[5]
Botulinum toxin - New mechanisms, new therapeutic directions? [J].
Chapple, C ;
Patel, A .
EUROPEAN UROLOGY, 2006, 49 (04) :606-608
[6]
Adverse events after botulinum A toxin injection for neurogenic voiding disorders [J].
De Laet, K ;
Wyndaele, JJ .
SPINAL CORD, 2005, 43 (07) :397-399
[7]
Del Popolo Giulio, 2001, Neurourology and Urodynamics, V20, P522
[8]
Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies [J].
Denys, Pierre ;
Corcos, Jacques ;
Everaert, Karel ;
Chartier-Kastler, Emmanuel ;
Fowler, Clare ;
Kalsi, Vinay ;
Nitti, Victor ;
Schulte-Baukloh, Heinrich ;
Schurch, Brigitte .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) :851-860
[9]
Botulinum toxin A in the overactive bladder: current status and future directions [J].
Dmochowski, Roger ;
Sand, Peter K. .
BJU INTERNATIONAL, 2007, 99 (02) :247-262
[10]
DYKSTRA DD, 1990, ARCH PHYS MED REHAB, V71, P24